secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0001558370-24-009009
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris shareholders elect two directors, approve say-on-pay, ratify auditor at 2024 annual meeting
--------------------------------------------------------------------------------

- Elected Christopher Molineaux (29.2M for, 16.2M withheld) and Vincent Milano (42.3M for, 3.1M withheld) as directors.
- Advisory vote on executive compensation approved: 29.0M for, 16.3M against, 21k abstain, with 12.5M broker non-votes.
- Ratified PricewaterhouseCoopers as auditor for FY2024: 56.6M for, 1.2M against, 23k abstain.
- Turnout of 81.09% (57.8M of 71.3M shares outstanding) present or represented at meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837024009009/0001558370-24-009009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837024009009/acrs-20240606x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer